Total synthesis of a new cancer fighter

21-Jun-2016 - USA

Rice University scientists have synthesized a novel anti-cancer agent, Thailanstatin A, which was originally isolated from a bacterial species collected in Thailand.

Nicolaou Group/Rice University

A schematic shows the synthesized anti-cancer agent Thailanstatin A. The Rice University lab of synthetic chemist K.C. Nicolaou has synthesized the molecule found in bacteria native to Thailand

Thailanstatin A fights cancer by inhibiting the spliceosome, the machinery in the cell that edits messenger RNA after transcription from DNA but before its translation into proteins. Rice synthetic chemist K.C. Nicolaou and his group reported their success.

Nicolaou and his colleagues specialize in the synthesis of potential therapeutic agents that are found in nature but in amounts too small for thorough biological evaluation or clinical use. He is best known for the total synthesis of paclitaxel, a drug commonly used to treat a number of cancers.

The researchers explained that the spliceosome, a complex of proteins and ribonucleoproteins that regulate DNA splicing, is more active and displays higher mutation rates in cancer cells than in healthy cells, which makes it a valid target for investigation.

"This cellular machinery edits mRNA as it emerges from the transcription of DNA through site-specific removal of introns (noncoding regions of DNA) and splicing the remaining exon (coding) sequences prior to translation," Nicolaou said. "Thailanstatin A interferes with this mechanism."

He said the synthesis of Thailanstatin A, first isolated from burkholderia thailandensis bacteria, opens the way to construct and test variations of the molecule. "These studies will be directed toward optimization of the pharmacological properties of this new natural product as part of a drug discovery and development program targeting new therapies for cancer," Nicolaou said.

The program can take two directions, he said: one directed toward high-potency compounds that could be used as payloads for antibody drug conjugates and the other toward selective agents that can kill cancer cells with minimal damage to healthy cells.

The first paradigm is currently a frontier approach for the development of targeted and personalized cancer therapies, while the second represents a more traditional approach that could also lead to powerful anti-cancer drugs, Nicolaou said. "Thailanstatin A exhibits just the right potency to be diverted to either approach through a reiterative molecular design, chemical synthesis and biological evaluation process," he said.

"We're excited about this new molecule and its analogs because of their unique biological properties and the prospects of working collaboratively with industrial and academic partners to advance them toward the clinic," Nicolaou said.

Original publication

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Estetrol proven to have an estrogen antagonistic effect on breast tumour tissue - Pantarhei Bioscience study findings demonstrate the disappearance of breast tumours during treatment with the human fetal estrogen Estetrol

Acacia Pharma initiates Phase IIA study with APD209 in cancer cachexia patients

MorphoSys und Astellas beginnen Antikörperpartnerschaft - Dritte therapeutische Allianz für MorphoSys in Japan

Addex Parkinson's Product Progressing in Early Clinical Trials

ArGEN-X initiates Phase Ib study of ARGX-110 in cancer

Prometic Finalizes Major Technology Licencing Agreement in Tunisia

Doug Berthiaume to Retire as Chairman of the Board of Waters Corporation - Chris O'Connell Elected as New Chairman

Horizon Discovery and Fox Chase Cancer Center announce collaboration to apply rAAV gene targeting in mouse embryonic stem cells and research into EGFR-therapy resistance. - Collaboration will establish a new Center Of Excellence in Mammalian Gene Editing

Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites

Addex Achieves Second Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc. - Data Confirm Non-Dopaminergic Approach to Treating Parkinson's Disease